Zhang M S, Zhou E F, Wang M Z, Li X M
Department of Pharmacology, Shanxi Medical College, Taiyuan, China.
Zhongguo Yao Li Xue Bao. 1993 Mar;14(2):133-6.
The effect of methylflavonolamine [4'-methyl-7-(2-hydroxy-3-isopropylamino-propoxy)-flavone hydrochloride, MFA], synthesized recently by the Shanghai Institute of Pharmaceutical Industry, on the development of atherosclerosis was studied in male New Zealand white rabbits fed cholesterol for 10 wk. MFA, 7 mg.kg-1 daily ip, did not significantly alter the serum total cholesterol, HDL, and triglyceride levels, but significantly lowered the aortic cholesterol and calcium contents. Atheromatous lesions covered 53.3 +/- 11.8% of the intimal surface of the aorta in the saline group and 11.3 +/- 2.3% in the MFA group (P < 0.01). We conclude that MFA suppresses cholesterol-induced atherosclerosis.
上海医药工业研究院最近合成的甲基黄酮醇胺[4'-甲基-7-(2-羟基-3-异丙氨基丙氧基)-黄酮盐酸盐，MFA]对喂胆固醇10周的雄性新西兰白兔动脉粥样硬化发展的影响进行了研究。每天腹腔注射7mg·kg-1的MFA，对血清总胆固醇、高密度脂蛋白和甘油三酯水平没有显著影响，但显著降低了主动脉胆固醇和钙含量。盐水组主动脉内膜表面动脉粥样硬化病变覆盖面积为53.3±11.8%，MFA组为11.3±2.3%（P<0.01）。我们得出结论，MFA可抑制胆固醇诱导的动脉粥样硬化。
